Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis.

ABSTRACT:

Purpose

To assess the present evidence regarding the efficiency, safety, and potential risks of pharmacotherapy used for Parkinson's disease psychosis (PDPsy) treatment.

Patients and methods

We searched the following databases: PubMed, the Cochrane Library, ISI Web of Science, and Embase using the following terms: atypical antipsychotics, pimavanserin, olanzapine, quetiapine, clozapine, Parkinson's disease and psychosis. We systematically reviewed all randomized placebo-controlled trials comparing an atypical antipsychotic with a placebo.

Results

A total of 13 randomized placebo-controlled trials for a total 1142 cases were identified involving pimavanserin (n=4), clozapine (n=2), olanzapine (n=3), and quetiapine (n=4). For each atypical antipsychotic, a descriptive s

SUBMITTER: Zhang H 

PROVIDER: S-EPMC6677378 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature